BROWSE BY TOPIC
- Bad Brokers
- Compliance Concepts
- Investor Protection
- Investments - Unsuitable
- Investments - Strategies
- Wall Street News
- Investments - Private
- Rules & Regulations
- Bad Advisors
- Boiler Rooms
- Terminations/Cost Cutting
- General News
- Donald Trump & Co.
- Big Banks
- Regulatory Sanctions
Stories of Interest
- Sarah ten Siethoff is New Associate Director of SEC Investment Management Rulemaking Office
- Catherine Keating Appointed CEO of BNY Mellon Wealth Management
- Credit Suisse to Pay $47Mn to Resolve DOJ Asia Probe
- SEC Chair Clayton Goes 'Hat in Hand' Before Congress on 2019 Budget Request
- SEC's Opening Remarks to the Elder Justice Coordinating Council
- Massachusetts Jury Convicts CA Attorney of Securities Fraud
- Deutsche Bank Says 3 Senior Investment Bankers to Leave Firm
- World’s Biggest Hedge Fund Reportedly ‘Bearish On Financial Assets’
- SEC Fines Constant Contact, Popular Email Marketer, for Overstating Subscriber Numbers
- SocGen Agrees to Pay $1.3 Billion to End Libya, Libor Probes
- Cryptocurrency Exchange Bitfinex Briefly Halts Trading After Cyber Attack
- SEC Names Valerie Szczepanik Senior Advisor for Digital Assets and Innovation
- SEC Modernizes Delivery of Fund Reports, Seeks Public Feedback on Improving Fund Disclosure
- NYSE Says SEC Plan to Limit Exchange Rebates Would Hurt Investors
- Deutsche Bank faces another challenge with Fed stress test
- Former JPMorgan Broker Files racial discrimination suit against company
- $3.3Mn Winning Bid for Lunch with Warren Buffett
- Julie Erhardt is SEC's New Acting Chief Risk Officer
- Chyhe Becker is SEC's New Acting Chief Economist, Acting Director of Economic and Risk Analysis Division
- Getting a Handle on Virtual Currencies - FINRA
We seek to provide information, insights and direction that may enable the Financial Community to effectively and efficiently operate in a regulatory risk-free environment by curating content from all over the web.
Stay Informed with the latest fanancialish news.
NEWSLETTERS & ALERTS
Shkreli Securities Fraud - Not an 'Open and Shut Case'
[Photo: Screen Grab from 2015 Interview / BBC.com]
by Howard Haykin
A third day of deliberations in the criminal trial of Martin Shkreli, 34, has ended with no verdict from the jury. On Wednesday, the jury had no questions for the federal judge in Brooklyn, NY, after having asked two relevant and pointed questions the prior day:
- “Do assets under management refer to a particular fund being described, or to all assets managed by the portfolio manager/general partner?” They further asked for a legal definition of assets under management.
- An expansion upon or elaboration of the term “fraudulent intent” - a key to the defense’s arguments that Mr. Shkreli is innocent.
While Martin Shkreli - a.k.a. "Pharma Bro" - is best known for his time as CEO of Turing Pharmaceuticals when, in 2015, he raised the price of anti-infection drug Daraprim by 5,000%, this criminal case stems from Shkreli's career as a hedge fund manager. Federal prosecutor say that between 2009 and 2014, when Shkreli managed hedge funds MSMB Capital and MSMB Healthcare and drug company Retrophin Inc., he lied to MSMB investors, lost their money and paid them back with stock and cash taken from Retrophin without the approval of that company's directors.
Judge's Response to Questions. With regard to "assets under management" (AUM), the judge advised the jury that there is no legal definition for that term. According to the testimony of one hedge fund investor, Mr. Shkreli had said he had AUM ranging from $40 million to $50 million. Another witness testified that Mr. Shkreli claimed to have AUM of $35 million. The defense contends that, while MSMB Capital never had more than $3 million under management, the larger figures properly attributed to Shkreli included the separate accounts of a wealthy Texas investor.
With regard to "fraudulent intent," the judge said that "is an issue in dispute for you, the jury, to resolve."